COPD News
News about the treatment and management of COPD, including current findings and information on promising new drugs.
First Biologic Medicine - Dupixent - Approved for COPD
On September 27, 2024, the U. S. Food and Drug Administration (FDA) approved the first biologic medicine - dupilumab (brand name: Dupixent) - for the maintenance treatment of patients with COPD. The indication is for those with uncontrolled COPD and elevated eosinophils in the blood. Studies show a 30 to 34% reduction in COPD flare-ups over one year and an improvement in breathing tests. Dupilumab is injected under the skin every two weeks.
New Nebulizer Medication -Ensifentrine - Approved for Treatment Of COPD
On June 26, 2024, the U. S. Food and Drug Administration approved a novel inhaled medication called ensifentrine (Ohtuvayre is the brand name) for the maintenance treatment of patients with COPD. This unique medication has both bronchodilator (opens airways) and anti-inflammatory properties and is delivered in a nebulizer twice a day.